The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

The first is a rapidly emerging understanding that a number of distinct tyrosine kinases ... pathways in clinical tumors (receptor and/or ligand-competitive antibodies, intrabodies, antisense ...

Cediranib is an orally available pan-VEGFR tyrosine kinase inhibitor with a half-life of 22 hours compatible with once daily dosing. 15 Cediranib has a subnanomolar 50% inhibitory concentration for ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors ... All antibodies were diluted in 0.1% ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...

DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ ...

DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ ...